The Drug Enforcement Administration (DEA) is proposing placing Propofol (Diprivan ™) among the controlled substances listed on Schedule IV. In a preview document that the DEA posted Oct. 25, which was anticipated to be published in the Federal Register later in the week, the agency outlined the pharmacologic properties of propofol and its propensity towards being diverted and abused. The agency justified proposing listing propofol among Schedule IV controlled substances, stating (a) propofol has a low potential for abuse relative to the drugs or substances on Schedule III, but has abuse potential comparable to Schedule IV substances methohexital and midazolam, (b) propofol has currently accepted medical use in the U.S., and (c) abuse of propofol may lead to limited psychological dependence or physical dependence relative to the drugs or other substances in Schedule III. Under a Schedule IV listing, the DEA says in its proposal that handling of propofol would be subject to specific requirements for registration, assuring security, labeling and packaging, inventory and recordkeeping, and other requirements, violations of which are subject to criminal liability.
Read the DEA posting http://www.ofr.gov/OFRUpload/OFRData/2010-27193_PI.pdf
Read the regulation listing current Schedule IV controlled substances at http://www.deadiversion.usdoj.gov/21...08/1308_14.htm